. 2018 Apr 3;15(7):659–665. doi: 10.7150/ijms.24453

Table 1.

Mainly clinical trial and targeted therapies in first-line metastatic colorectal treatment.

Study	Design	RR	p-value	Median PFS	p-value	Median OS	p-value
Saltz et al. ¹⁶	Bevacizumab + FOLFOX/XELOX	-		9.4		-
	vs.		-		0.002		-
	FOLFOX/XELOX	-		8		-
Hurwitz et al. ¹⁷	Bevacizumab + FOLFIRI	44.8		10.6		20.3
	vs.		0.004		<0.001		<0.001
	FOLFIRI	34.8		6.2		15.6
Bokemeyer et al. ²⁶	Cetuximab + FOLFOX	61		7.7		-
	vs.		0.011		0.0163		-
	FOLFOX	37		7.2		-
Van Cutsem et al. ²⁸	Cetuximab + FOLFIRI	57.3		9.9		23.5
	vs.		0.001		0.0012		0.0093
	FOLFIRI	39.7		8.4		20.0
Van Cutsem et al. ²⁹	Cetuximab + FOLFIRI	46.9		8.9		19.9
	vs.		0.004		0.048		0.31
	FOLFIRI	38.7		8.0		18.6
PRIME study ³¹	Panitumumab + FOLFOX	-		9.6		23.9
	vs.		-		0.02		0.072
	FOLFOX	-		8.0		19.7

RR: response rate (%). PFS: progression free-survival (months). OS: overall survival (months).